425: Boston Scientific to Acquire Penumbra in Cash and Stock Deal

Boston Scientific Corporation announced a definitive agreement to acquire Penumbra, Inc. through a merger, offering Penumbra shareholders a choice of cash or Boston Scientific common stock.

Summary

• Boston Scientific Corporation (Parent) entered into an Agreement and Plan of Merger with Pinehurst Merger Sub, Inc. (Merger Sub), a wholly-owned subsidiary, and Penumbra, Inc. (Company) on January 14, 2026.
• Merger Sub will merge into Penumbra, with Penumbra surviving as a wholly-owned subsidiary of Boston Scientific.
• Each Penumbra common share will be converted into the right to receive, at the holder's election, either $374.00 in cash (Cash Consideration) or 3.8721 shares of Boston Scientific common stock (Stock Consideration).
• The election is subject to a proration mechanism: 73.26% of Penumbra shares will receive cash, and 26.74% will receive stock.
• Outstanding Penumbra stock options with an exercise price less than the Equity Award Consideration Value will be canceled and converted into a mix of $274.00 cash and 1.0353 Boston Scientific shares per underlying Penumbra share, adjusted for exercise price and taxes.
• Penumbra restricted stock units (RSUs) granted prior to January 1, 2026, or those that vest upon closing, will vest and convert into a mix of $274.00 cash and 1.0353 Boston Scientific shares per underlying Penumbra share, adjusted for taxes.
• Other Penumbra RSUs will be assumed by Boston Scientific and converted into Boston Scientific RSUs based on a specified conversion ratio, retaining their original vesting terms.
• The Penumbra Employee Stock Purchase Plan (ESPP) will be terminated immediately prior to the merger's effective time, with accumulated payroll deductions returned to participants.
• Consummation of the merger is subject to Penumbra Stockholder Approval, regulatory clearances (including HSR Act), effectiveness of Boston Scientific's Form S-4 registration statement, NYSE listing approval for Boston Scientific shares, and absence of material adverse effects for either company.

Sentiment

Score: 7

Explanation: The filing announces a definitive merger agreement, which is a significant and generally positive event for Penumbra shareholders, offering a premium and liquidity. For Boston Scientific, it represents a strategic expansion. The deal structure is clear, and substantial termination fees indicate commitment. However, inherent risks associated with regulatory approvals and integration temper the sentiment slightly.

Positives

• Penumbra shareholders are offered a clear exit strategy with a fixed cash price of $374.00 per share or a fixed exchange ratio of 3.8721 Boston Scientific shares, providing a premium and liquidity.
• The agreement includes a Parent Termination Fee of $900,000,000 payable to Penumbra if the merger is terminated due to failure to obtain requisite regulatory approvals, providing significant downside protection for Penumbra.
• Penumbra's current and former directors and officers will receive indemnification and directors and officers liability insurance for a period of six years after the merger, consistent with existing policies.
• Continuing employees of Penumbra will receive base salary/wage rates no less favorable, incentive opportunities no less favorable in aggregate, and substantially comparable employee benefits for one year following the Effective Time.

Negatives

• Penumbra shareholders will cease to have direct ownership in Penumbra and its future growth prospects.
• The proration mechanism for cash and stock elections means shareholders may not receive their preferred mix of consideration, potentially leading to unexpected tax consequences or exposure to Boston Scientific's stock price fluctuations.
• Penumbra's business operations are subject to various restrictions during the pre-closing period, requiring Boston Scientific's consent for certain actions, which could limit strategic flexibility.
• The merger is subject to numerous conditions, including regulatory approvals, which could delay or prevent the transaction from closing.

Risks

• Failure to obtain the required Penumbra Stockholder Approval could prevent the merger from being consummated.
• Regulatory authorities may not grant necessary approvals or clearances (e.g., under the Hart-Scott-Rodino Antitrust Improvements Act and other Antitrust Laws) or may impose burdensome conditions, including divestitures, which could delay or prevent the merger.
• The effectiveness of the registration statement on Form S-4 for Boston Scientific shares and their approval for listing on the NYSE are conditions to closing.
• The occurrence of a 'Company Material Adverse Effect' or 'Parent Material Adverse Effect' could lead to the termination of the merger agreement.
• Economic conditions, foreign currency fluctuations, geopolitical events, manufacturing/supply chain disruptions, cybersecurity events, public health emergencies, and labor shortages could impact the financial and business performance of the combined entity.
• Variations in outcomes of ongoing and future clinical trials and market studies, new product introductions, and expected procedural volumes are inherent business risks.
• Challenges in the closing and integration of Penumbra's operations, including potential disruptions in relationships with employees, customers, or suppliers, could affect anticipated benefits.
• Litigation related to the transaction could arise, potentially delaying or impacting the merger.

Future Outlook

The filing outlines the terms of a definitive merger agreement, indicating Boston Scientific's strategic intent to acquire Penumbra. It includes forward-looking statements regarding the financial and business impact, anticipated benefits, and timing of the transaction, but these are subject to various risks and uncertainties. The successful integration of Penumbra's operations is an anticipated benefit, and the combined entity is expected to enhance its market position in specific medical device segments.

Management Comments

• The Penumbra Board unanimously determined that the Agreement and Plan of Merger, the merger, and other transactions are advisable, fair to, and in the best interests of Penumbra and its stockholders.
• The Penumbra Board resolved to recommend adoption of the Merger Agreement by the stockholders of Penumbra.
• The Boston Scientific Board duly authorized and approved the execution, delivery, and performance of the Merger Agreement and the consummation of the transactions, including the merger and the issuance of Boston Scientific shares.

Industry Context

This acquisition represents a significant consolidation within the medical device industry, specifically targeting the neurovascular and peripheral vascular spaces where Penumbra's products are focused. Such strategic mergers are common as larger industry players like Boston Scientific seek to expand their product portfolios, enhance technological capabilities, and gain market share in high-growth or specialized segments. The transaction could strengthen Boston Scientific's competitive position and offer a broader range of solutions to healthcare providers.

Comparison to Industry Standards

• The offering of both cash and stock consideration with a proration mechanism is a common and flexible approach in large-scale mergers, allowing target shareholders to choose their preferred form of value while managing the acquirer's capital structure and dilution.
• The substantial termination fees ($525 million for Penumbra, $900 million for Boston Scientific) are consistent with industry norms for transactions of this size, reflecting the commitment of both parties and providing a measure of deal certainty or compensation for failure.
• Provisions for indemnification and D&O insurance for the target company's directors and officers, as well as employee benefit protections for continuing employees, are standard inclusions in merger agreements to ensure continuity and mitigate risks for key stakeholders.
• The extensive regulatory review process, particularly under antitrust laws like the HSR Act, is a typical hurdle for significant mergers in the healthcare sector, which often face scrutiny due to potential market concentration concerns.

Management Changes

Corporate Governance

Legal Proceedings

• The Company will give Boston Scientific reasonable opportunity to participate in the defense of any 'Transaction Litigation' (actions brought by Penumbra's stockholders or other persons against Penumbra or its directors/officers arising out of or relating to the merger agreement or transactions).
• The Company will not settle any Transaction Litigation without Boston Scientific's prior written consent (which shall not be unreasonably withheld, conditioned, or delayed).

Related Party Transactions

• As of the date of the Agreement, there are no transactions, contracts, arrangements, commitments, or understandings between Penumbra or its subsidiaries, on the one hand, and any of Penumbra's Affiliates, on the other hand, that would be required to be disclosed under Item 404 of Regulation S-K under the Securities Act.

Stakeholder Impact

• **Penumbra Shareholders**: Will receive a premium for their shares, with the option to choose between cash and Boston Scientific stock, providing liquidity and continued investment opportunity in the combined entity.
• **Boston Scientific Shareholders**: Will experience dilution from the issuance of new shares but gain strategic assets, expanded market share, and enhanced product portfolio in key medical device segments.
• **Penumbra Employees**: Continuing employees are guaranteed comparable compensation and benefits for one year post-merger, but changes in management and corporate structure are anticipated.
• **Customers**: Potential for expanded product offerings and services from the combined Boston Scientific-Penumbra entity.
• **Regulatory Authorities**: The merger will undergo scrutiny from antitrust and other regulatory bodies, potentially leading to conditions or divestitures to ensure market competition.

Next Steps

• Boston Scientific and Penumbra will jointly prepare and file a proxy statement/prospectus (Form S-4) with the SEC.
• Boston Scientific will use reasonable best efforts to have the Form S-4 declared effective under the Securities Act.
• Penumbra will establish a record date and convene a stockholder meeting to obtain the Penumbra Stockholder Approval.
• The parties will cooperate to obtain all necessary regulatory approvals and clearances, including the expiration or termination of waiting periods under the HSR Act.
• Boston Scientific will cause the shares to be issued in the merger to be approved for listing on the NYSE.
• Penumbra will cooperate to de-list its shares from the NYSE and deregister them under the Exchange Act as promptly as practicable after the Effective Time.

Key Dates

Keywords

Merger, Acquisition, Boston Scientific, Penumbra, Medical Devices, Healthcare, SEC Filing, 8-K, Cash and Stock Deal, Corporate Governance, Regulatory Approval, Shareholder Vote, Equity Awards, Antitrust